Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Danielle Fredman, Yulia Volchek, MD, Gabriel Heering, Keren Shichrur, PhD, Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Elena Ribakovsky, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD, Jonathan Canaani, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134771

Published: 2020

Journal Articles

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Ohad Benjamini, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Meirav Kedmi, MD, Adrian Duek, MD, Drorit Merkel, MD, Merav Leiba, MD, Ivetta Danylesko, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, Yulia Volchek, MD

Blood (2016) 128 (22): 5429.

https://doi.org/10.1182/blood.V128.22.5429.5429

Published: 2016

Journal Articles

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Adi Shacham Abulafia, MD, Pia Raanani, MD, David Lavie, MD, Yulia Volchek, MD, Ron Ram, MD, Ilana Hellmann, MD, Liat Shargian, MD, Anna Gourevietch, MD, Evgeni Chubar, MD, Roy Ratzon, BSC, Uri Rozovski, MD

Blood (2015) 126 (23): 5155.

https://doi.org/10.1182/blood.V126.23.5155.5155

Published: 2015

Journal Articles

Missing HLA C Group 1 Ligand In Patients With AML and MDS Is Associated With Reduced Risk Of Relapse After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning

Avichai Shimoni, MD, Massimo Bernardi, MD, Ronit Yerushalmi, MD, Jacopo Peccatori, MD, Noga Shem-Tov, MD, Alessandro Lo Russo, MD, Yulia Volchek, MD, Luca Vago, MD, PhD, Chiara Bonini, MD, Maria Teresa Lupo Stanghellini, MD, Arnon Nagler, MD, MSc, Fabio Ciceri

Blood (2013) 122 (21): 4634.

https://doi.org/10.1182/blood.V122.21.4634.4634

Published: 2013

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later

Avichai Shimoni, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD, MSc

Blood (2013) 122 (21): 4635.

https://doi.org/10.1182/blood.V122.21.4635.4635

Published: 2013

Journal Articles

The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients

Ivetta Danylesko, MD, Rina Sareli, Nira Bloom-Varda, Ronit Yerushalmi, Noga Shem-Tov, MD, Yulia Volchek, MD, Avichai Shimoni, MD, Arnon Nagler, MD, MSc

Blood (2013) 122 (21): 3275.

https://doi.org/10.1182/blood.V122.21.3275.3275

Published: 2013

Journal Articles

Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen

Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ivetta Danylesko, MD, Abraham Avigdor, MD, Arnon Nagler, MD, MSc, Avichai Shimoni

Blood (2013) 122 (21): 3380.

https://doi.org/10.1182/blood.V122.21.3380.3380

Published: 2013

Journal Articles

Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

Avichai Shimoni, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 655.

https://doi.org/10.1182/blood.V118.21.655.655

Published: 2011

Journal Articles

Maintenance Therapy with Nilotinib (Tasigna) Post Allogeneic Stem Cell Transplantation (AlloSCT) for Advanced (>CP 1 ) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Arnon Nagler, MD, Yulia Volchek, MD, Nira Bloom, Ph.D, Raz Somech, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD

Blood (2011) 118 (21): 2011.

https://doi.org/10.1182/blood.V118.21.2011.2011

Published: 2011

Journal Articles

Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,

Avichai Shimoni, MD, Eran Tallis, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 4096.

https://doi.org/10.1182/blood.V118.21.4096.4096

Published: 2011

Journal Articles

Allogeneic Stem-Cell Transplantation for AML and MDS with Tresosulfan Compared with Busulfan-Based Regimens; Reduced Toxicity Vs. Reduced Intensity

Avichai Shimoni, MD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 495.

https://doi.org/10.1182/blood.V118.21.495.495

Published: 2011

Journal Articles

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 3473.

https://doi.org/10.1182/blood.V116.21.3473.3473

Published: 2010

Journal Articles

Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogentic Responses (CCyR)

Izhar Hardan, Yulia Volchek, MD, Tali Tohami, MD, PhD, Ninette Amariglio, Luba Trakhtenbrot, Maya Koren-Michowitz, Arnon Nagler, M.D.

Blood (2010) 116 (21): 4898.

https://doi.org/10.1182/blood.V116.21.4898.4898

Published: 2010

Journal Articles

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, MD, Izhar Hardan, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 2314.

https://doi.org/10.1182/blood.V116.21.2314.2314

Published: 2010

Journal Articles

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, Noga Shem-Tov, MD, Izhar Hardan, Yulia Volchek, MD, Hannah Maayaan, MD, Ronit Yerushalmi, Arnon Nagler, MD

Blood (2009) 114 (22): 2255.

https://doi.org/10.1182/blood.V114.22.2255.2255

Published: 2009

Journal Articles

A Pilot Study of Combined Escalated BEACOPP-ABVD Therapy for Advanced Hodgkin’s Lymphoma Patients with High IPS Score: The Israel Cooperative Lymphoma Group.

Abraham Avigdor, MD, Shlomo Bulvik, MD, Noga Shemtov, MD, Itai Levi, MD, Miriam Berkowicz, MD, Dina Ben-Yehuda, MD, Dorit Blickstein, MD, Neta Goldschmidt, MD, Alexander Gural, MD, Abraham Kornberg, MD, Dianna Libster, MD, Drorit Merkel, MD, Elizabeth Naparstek, MD, Pia Raanani, MD, Batia Roth, MD, Yulia Volchek, MD, Arnon Nagler, MD, Isaac Ben-Bassat, MD, Aaron Polliack, MD

Blood (2004) 104 (11): 4576.

https://doi.org/10.1182/blood.V104.11.4576.4576

Published: 2004

NARROW

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Missing HLA C Group 1 Ligand In Patients With AML and MDS Is Associated With Reduced Risk Of Relapse After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning

Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later

The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients

Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen

Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

Maintenance Therapy with Nilotinib (Tasigna) Post Allogeneic Stem Cell Transplantation (AlloSCT) for Advanced (>CP 1 ) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,

Allogeneic Stem-Cell Transplantation for AML and MDS with Tresosulfan Compared with Busulfan-Based Regimens; Reduced Toxicity Vs. Reduced Intensity

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogentic Responses (CCyR)

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

A Pilot Study of Combined Escalated BEACOPP-ABVD Therapy for Advanced Hodgkin’s Lymphoma Patients with High IPS Score: The Israel Cooperative Lymphoma Group.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only